{"entity":{"id":"errfi1","kind":"target","name":"ERRFI1","aka":["ERBB receptor feedback inhibitor 1","MIG-6","GENE-33"],"tldr":"ERRFI1 (ERBB receptor feedback inhibitor 1) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Biliary tract cancer and Non-small-cell lung cancer.","summary":"Negative regulator of EGFR signalling in skin morphogenesis. Acts as a negative regulator for several EGFR family members, including ERBB2, ERBB3 and ERBB4. Inhibits EGFR catalytic activity by interfering with its dimerisation.\n\nCIViC holds 2 clinical evidence items and 0 assertions across 4 variants, naming Erlotinib and Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor.","asOf":"2026-09-23","links":[{"label":"HGNC HGNC:18185","url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:18185"},{"label":"UniProt Q9UJM3","url":"https://www.uniprot.org/uniprotkb/Q9UJM3/entry"},{"label":"NCBI Gene 54206","url":"https://www.ncbi.nlm.nih.gov/gene/54206"},{"label":"Ensembl ENSG00000116285","url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000116285"}],"tags":["cancer-genes-wave"],"related":["civic"],"cancers":["cholangiocarcinoma","nsclc"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: CIViC lists 2 therapies; CIViC holds 2 clinical evidence items on its variants. Evidence tier \"clinical-evidence\" is the strongest of those signals.","Prevalence not recorded: none of the sources gives a positivity rate."],"provenance":{"editedBy":"scripts/fetch-cancer-genes.ts (CIViC, Open Targets, IntOGen, HGNC, UniProt)","editedOn":"2026-09-23"},"symbol":"ERRFI1","role":["drug-target","biomarker"],"evidenceTier":"clinical-evidence","sources":[{"label":"HGNC HGNC:18185","url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:18185","note":"approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)"},{"label":"UniProt Q9UJM3","url":"https://www.uniprot.org/uniprotkb/Q9UJM3/entry","note":"protein name, function text, keywords and locations (REST API)"},{"label":"CIViC gene ERRFI1","url":"https://civicdb.org/features/12271","note":"2 evidence items, 0 assertions, 4 variants; diseases: Cholangiocarcinoma, Lung Non-small Cell Carcinoma (GraphQL API, CC0)"}],"hgnc":"HGNC:18185","ensembl":"ENSG00000116285","uniprot":"Q9UJM3","entrez":"54206","biology":"Negative regulator of EGFR signalling in skin morphogenesis. Acts as a negative regulator for several EGFR family members, including ERBB2, ERBB3 and ERBB4. Inhibits EGFR catalytic activity by interfering with its dimerisation. Inhibits autophosphorylation of EGFR, ERBB2 and ERBB4. Important for normal keratinocyte proliferation and differentiation. Plays a role in modulating the response to steroid hormones in the uterus. Location: Cytoplasm; Cell membrane; Nucleus (UniProt). Locus 1p36.23 (HGNC).","whereFound":["Biliary tract cancer: CIViC evidence names this disease","Non-small-cell lung cancer: CIViC evidence names this disease"],"targetClass":"other","prevalence":[]},"route":"/targets/errfi1/","neighbours":{"collection":[{"id":"civic","kind":"collection","name":"CIViC","route":"/collections/civic/"}],"cancer":[{"id":"cholangiocarcinoma","kind":"cancer","name":"Biliary tract cancer (cholangiocarcinoma)","route":"/cancers/cholangiocarcinoma/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}]}}